Biocon partner Viatris gets Complete Response Letter from USFDA for Bevacizumab license application Ruchika Sharma13 Feb 2023 5:43 AMBevacizumab is a medication used to treat a number of types of cancers and a specific eye disease.
Viatris closes acquisitions of Famy Life Sciences, Oyster Point Pharma to establish eye care division Ruchika Sharma4 Jan 2023 7:45 AMThe aggregate acquisition price for the Famy Life Sciences business is expected to be approximately $280 million.
Biocon Biologics names Shreehas Tambe as new MD, CEO Ruchika Sharma5 Dec 2022 10:45 AMBengaluru: Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced today that Shreehas Tambe, Deputy CEO of Biocon Biologics, has been...
Viatris sells global biosimilars business to Biocon Biologics for USD 3 billion Ruchika Sharma30 Nov 2022 5:53 AMThe acquisition provides Biocon Biologics with direct commercial capabilities and supporting infrastructure in the advanced markets and several...
Biotechnology major Biocon net profit declines 11 percent to Rs 168 crore in Q2 Ruchika Sharma15 Nov 2022 9:00 AMMazumdar-Shaw said the consolidation of Viatris' global biosimilars business and the strategic vaccines alliance with Serum Institute will add to the...
Biocon arm wins Asia IP Elite Award Ruchika Sharma12 Nov 2022 7:30 AMA record 80 organisations around the Asia-Pacific region featured in this year's event, which was organized after a gap of two years.
Viatris acquires Famy Life Sciences ophthalmology business for Rs 2,500 crore Ruchika Sharma8 Nov 2022 8:00 AMViatris is taking over a business consisting of a strong ophthalmic portfolio of phase 3 clinical assets in diseases such as dry eye, presbyopia, and...
US Supreme Court turns down Novartis bid to block launch of multiple sclerosis drug Gilenya generics Ruchika Sharma15 Oct 2022 8:00 AMNovartis settled with some of the drugmakers it had sued, allowing for some Gilenya generics before a key patent's 2027 expiration.
Merck VS Mylan Pharma: US Court of Appeals for the Federal Circuit rules in favor of Merck in Sitagliptin Dihydrogen Phosphate patent lawsuit Ruchika Sharma2 Oct 2022 11:30 AMThe ruling from the U.S. Court of Appeals provides JANUVIA, JANUMET and JANUMET XR patent protection through May 2027, which includes six (6) months...
Natco Pharma partner Viatris to launch first generic version of Nexavar tablets in US Ruchika Sharma1 Jun 2022 9:12 AMSorafenib is prescribed for treatment of unresectable Hepatocellular Carcinoma (HCC), advanced Renal Cell Carcinoma (RCC) and Differentiated Thyroid...
Biocon Biologics, Viatris launch cancer medicine Abevmy in Canada Ruchika Sharma20 May 2022 9:32 AMAbevmy is a recombinant humanized monoclonal antibody that selectively binds to human vascular endothelial growth factor (VEGF) and neutralizes its...
Biocon arm to purchase Viatris biosimilars business for USD 3.335 billion MD Bureau28 Feb 2022 7:32 AMBengaluru: Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has announced that the company has entered into a definitive agreement with its partner...
